Prophylactic Cranial Irradiation Dose for ALL
When prophylactic cranial irradiation is indicated for ALL, the recommended dose is 18 Gy delivered at 1.5–1.8 Gy per fraction 1.
Key Recommendation
The most recent and authoritative guidance comes from the 2025 NCCN Pediatric ALL Guidelines, which explicitly state that if cranial radiation is performed, the recommended dosing is 18 Gy at 1.5–1.8 Gy/fraction 1. This represents the current standard of care and reflects a shift toward reduced-dose approaches compared to historical practices.
Critical Context: Cranial Radiation is Increasingly Avoided
Modern treatment protocols strongly favor avoiding cranial irradiation altogether when possible, due to significant concerns about late effects on quality of life 1. The NCCN guidelines emphasize that:
- Cranial RT is often avoided in favor of intrathecal chemotherapy and systemic therapy (high-dose methotrexate, cytarabine, pegaspargase/calaspargase) 1
- This shift is driven by concerns about long-term neurocognitive impairment, endocrine dysfunction, and secondary malignancies
When Cranial Irradiation IS Used
Cranial radiation may still be indicated in specific high-risk scenarios:
Indications:
- CNS-3 disease at diagnosis (WBC count ≥5/μL in CSF with lymphoblasts, or clinical CNS symptoms) 1
- Protocol-specific requirements for certain high-risk patients
- T-cell ALL in some protocols, though timing and necessity vary 1
Important Caveat:
The use of cranial radiation for CNS-3 disease varies based on protocol, and patients should be treated according to their specific treatment protocol 1.
Evidence for Dose Reduction
Historical context supports the current 18 Gy recommendation:
- Older studies used 24 Gy, but research demonstrated that 20 Gy was equally effective with less toxicity (reduced brain atrophy and leukoencephalopathy) 2
- 18 Gy has become the modern standard, representing further dose reduction while maintaining CNS control 1
- Studies from the 1980s showed that reducing from 24 Gy to 18 Gy maintained efficacy for CNS prophylaxis 3
Alternative Strategies (Preferred When Feasible)
High-dose methotrexate (HD-MTX) has demonstrated equivalent efficacy to cranial irradiation in many patient populations, particularly in young children and standard-risk patients 4:
- HD-MTX (8 g/m² × 3 doses) showed 92% 5-year event-free survival versus 75% with cranial RT in young children with T-ALL 4
- No CNS recurrences occurred in the HD-MTX group 4
- This approach avoids the neurocognitive and endocrine complications of cranial irradiation
Special Populations
Transplant Setting:
For adults with high-risk ALL undergoing allogeneic transplant with total body irradiation (TBI):
- Low-dose cranial boost (6 Gy) may be considered in select high-risk patients 5
- However, recent data suggests that cranial boost may not improve outcomes in patients without prior CNS involvement 6
- The benefit of cranial boost in the transplant setting remains unestablished 6
Adolescents and Young Adults:
- Pediatric-inspired regimens with intensive intrathecal and systemic chemotherapy are preferred over cranial irradiation 7
- This approach prioritizes quality of life while maintaining disease control
Clinical Algorithm
For patients requiring CNS-directed therapy:
- First-line approach: Intensive intrathecal chemotherapy (methotrexate, cytarabine, corticosteroids) + systemic high-dose methotrexate or cytarabine
- If cranial irradiation is protocol-mandated or clinically necessary: 18 Gy at 1.5–1.8 Gy/fraction
- Never exceed 18 Gy in modern protocols unless treating active CNS disease (not prophylaxis)
Common Pitfalls to Avoid
- Do not use historical doses of 24 Gy for prophylaxis—this increases toxicity without improving outcomes
- Do not automatically give cranial RT to all patients—modern protocols reserve this for specific high-risk subsets
- Do not omit CNS-directed therapy entirely—over 50% of patients will develop CNS leukemia without prophylaxis 1
- For T-cell ALL, follow protocol-specific timing for cranial radiation, as optimal timing remains unclear 1